title: [A randomized controlled study on the efficacy of modified sclerotherapy in treating angioma of ear, nose and throat].
abstract: OBJECTIVE
  To evaluate the efficacy and security of modified and traditional sclerotherapy in treating angioma in ENT.
  
  
  METHODS
  For the Angioma of derma and hypodermis (naso face, auricles, neck) 56 cases and 82 cases of mucosa and hypomucosa (the cavities of nose, throat and mouth) were randomized divided into 2 groups each.: The 5% Sodium Morrhate + Triamcinolone Acetonide (The Modified Sclerotherapy n = 28, n = 41) and only 5% Sodium Morrhate (Traditional Sclerotherapy n = 28, n = 41) were respectively injected into bodies of Angioma, as one time a week for 2-6 weeks, on average 19 days.
  
  
  RESULTS
  The rates of cure and effective for Modified and Traditional Sclerotherapies were 84.1%, 65.2% and 91.3%, 85.5% respectively. There is a significant in statistics for effective rates and there is a notable difference in cured rates between the two therapies. It shows that Modified Sclerotherapy has an obvious advantage (P < 0.05). Although the efficacy is similar between the two therapies for angioma of mucosa and hypomucosa, the difference has a significant in efficacy for angioma of derma and hypoderma between the two therapies (P < 0.05) and the side-effects were very slight for Modified Sclerotherapy.
  
  
  CONCLUSIONS
  There is a more prominent efficacy and security for Modified Sclerotherapy than Traditional Sclerotherapy.
authors.affiliation: Department of Otolaryngology, Huaxi Hospital, Sichuan University, Chengdu 610041.
authors.forename: Kaiyuan
authors.initials: K
authors.lastname: Zhou
authors.forename: Chuanyu
authors.initials: C
authors.lastname: Liang
authors.forename: Keqin
authors.initials: K
authors.lastname: Yang
authors.forename: Lihong
authors.initials: L
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006391:Hemangioma / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D010039:Otorhinolaryngologic Neoplasms / Q000628:therapy*; D015911:Sclerotherapy; D012976:Sodium Morrhuate / Q000008:administration & dosage; D014222:Triamcinolone Acetonide / Q000008:administration & dosage
chemical_list: D012976:Sodium Morrhuate; D014222:Triamcinolone Acetonide